The kit is approved for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including breast cancer.
The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The firm said it delivered 6,408 billable tests during Q4, an increase of 52 percent year over year.
The findings implicated immune response, lipid metabolism, tau binding proteins, and amyloid precursor protein metabolism pathways in disease risk.
Researchers defined six malignant cell clusters with single-cell transcriptomes and genotypes for thousands of acute myeloid leukemia cells.
The company also reported higher operating costs due to an expansion of its US sales force, as well as its European commercial and laboratory staff.
The firm plans to submit its Idylla MSI test for 510(k) clearance from the US Food and Drug Administration after receiving CE-IVD approval this morning.
Centogene said it will conduct molecular diagnostic testing using deletion/duplication analysis and full-length sequencing of the DMD gene.
At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.
The firms are focusing on developing a rapid diagnostic test for African swine fever that can be used on GNA's portable MDx platform.
The test uses qPCR to measure the methylation level of three bladder cancer-specific biomarkers in patient urine samples.
The firm also reported full-year 2018 sales of €2.42 billion, a year-over-year increase of 6 percent on a reported basis, or 10 percent organically.
Biocept will use its liquid biopsy assay to test cerebrospinal fluids of patients diagnosed with certain cancers and then compare results to standard methods.
Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.
The Personal Genome Sequencing Outcomes (PeopleSeq) Consortium surveyed more than 500 early adopters who underwent personal genome or exome sequencing.
The company has been gearing up to submit its Acuitas AMR Gene Panel product to the US Food and Drug Administration for regulatory clearance.
The partnership will accelerate the development of molecular diagnostics in the Chinese market, Minneapolis-based Bio-Techne said.
Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.
Genome- and exome-wide association analysis on inflammatory bowel disease patients with or without thiopurine-induced myelosuppression revealed new and known risk genes.
The consortium plans to develop recommendations on the best practices for implementing clinical whole-genome sequencing for rare genetic disease diagnosis.
The NGS assay is designed to help physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies.
The German firm said that researchers can now run its GynTect cervical cancer assay on Roche Diagnostics' Cobas z 480 analyzer.
The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.
Danaher has commenced its concurrent offerings of $1.35 billion of shares of its common stock and $1.35 billion of shares of its mandatory convertible preferred stock.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.